Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

ETF What's Up

You may unsubscribe at any time by clicking the “unsubscribe” link within the emailed newsletter. By signing up, you agree to our Privacy Policy and Terms and Conditions.

371470

Mirae Asset TIGER Biotech Solactive ETF

Passive ETFEquity
Not rated

The 371470 Exchange Traded Fund (ETF) is provided by Mirae Asset Global Investments. It is built to track an index: Solactive China Biotech Index. The 371470 ETF provides physical exposure, so by buying it you actually own parts of all the 30 underlying holdings. This share class generates a stream of income by distributing dividends.

Advertisement

Advertisement

₩8,435
-₩55 (-0.65%) 2 days ago
12:00 AM 09/04/26 Closed
1D price range
₩8,360₩8,560
52W price range
₩7,160₩9,980
YTD Perf.
-0.91%
YTD Flows
Annualized volatility
Fund AuM
€29M
Share class AuM
€29M
TTM Yield
Tracking Error
Tracking Difference
ISIN
KR7371470006
TER
0.59%
Inception date
12/3/2020
Replication method
Dividend policy
Compare similar ETFs
API
PerformanceDec 30, 2025 - Sep 3, 2026
-10%-5%0%5%10%15%JANMARMAYJULSEP
Flows
Join for free to unlock
Data as of 07/31/26
Healthcare
99.60%
Unavailable
0.40%
Latest 371470 news

No content available for this fund

FAQ about 371470

371470 is a Passive ETF. This ETF provides exposure to Chinese Biotechnology Equities.
371470 tracks the Solactive China Biotech Index - CNY, through a optimized sampling replication method.
371470 carries a total expense ratio (TER) of 0.59%, indicating the annual cost for holding the fund.
371470 was introduced to the market on December 3, 2020. It trades on South Korea
Mirae Asset TIGER Biotech Solactive ETF, 371470, is provided by Mirae Asset Global Investments. Learn more about Mirae Asset Global Investments here.
371470 oversees €29M in assets as of September 3, 2026.
371470 follows a distributing dividend policy, meaning it pays out income to investors. As of September 3, 2026, its 12-month trailing yield was 0.72%.
As of July 31, 2026, 371470 has significant geographic allocations in China, Switzerland and Hong Kong.
As of July 31, 2026, 371470 focuses largely on Healthcare.
As of July 31, 2026, 371470 holds 30 positions in its portfolio, with 78.31% of assets concentrated in its top 15 holdings.
As of July 31, 2026, 371470 top three holdings include BeOne Medicines Ltd., WuXi AppTec Co., Ltd. and WuXi Biologics (Cayman), Inc..
The base currency of 371470 is KRW.
Data as of 07/31/26
BeOne Medicines Ltd.
9.70%
WuXi AppTec Co., Ltd.
9.18%
WuXi Biologics (Cayman), Inc.
8.96%
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
8.85%
Innovent Biologics, Inc.
8.84%
Akeso, Inc.
6.16%
Sino Biopharmaceutical Ltd.
4.32%
Hansoh Pharmaceutical Group Co., Ltd.
3.88%
3SBio, Inc.
3.25%
Shanghai RAAS Blood Products Co., Ltd.
2.90%

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:
  • More fund data
  • Compare up to 3 funds
  • More screener filters
  • Edit screener columns from 100+ metrics
  • Watchlists for saving your research
  • Portfolio construction and analysis
  • Personal dashboard for live monitoring

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight